Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
BELLINGS Intelligence Score: 10
Why it matters
The downgrade of Novo Nordisk after a significant stock price decline is notable for equity investors but does not directly impact credit markets or broader financial conditions relevant to sophisticated credit professionals.
Sources
MarketWatch
Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.